Deletion of the hPER 3 gene on chromosome 1 p 36 in recurrent ER-positive breast cancer
Joan Climent,Jesus Perez-Losada,David A. Quigley,Il-Jin Kim,Reyno Delrosario,Kuang-Yu Jen,Ana Bosch,Robert D. Cardiff,Ana Lluch,Jian-Hua Mao,Allan Balmain
2009-01-01
Abstract:The PER3 gene is a member of a conserved family of genes linked to control of the circadian cycle in flies, mice and humans. We show that deletion of the PER3 gene located on human chromosome 1p36 is directly related to tumor recurrence in patients with estrogen receptor (ER) positive breast cancers treated with Tamoxifen. Low expression of PER3 mRNA is associated with poor prognosis, particularly in a subset of tumors that are ER-positive, and either luminal-A type or ERBB2-positive tumors. Mice deficient in Per3 showed increased susceptibility to breast cancer induced by carcinogen treatment or by over-expression of Erbb2. Epidemiological evidence suggests that disruption of sleep patterns plays a significant role in susceptibility to breast cancer, and inherited genetic variants in PER3 have previously been associated with both phenotypes. Disruption of PER3 function could provide a link between deregulation of sleep homeostasis and breast tumorigenesis, and may serve as an indicator of probability of tumor recurrence in patients with ER-positive tumors. INTRODUCTION Chromosomal region 1p36 is among the most commonly deleted regions in human cancers. Deletion of 1p36 is especially frequent in breast tumors and is associated with progression and lymph node metastasis, poor prognosis higher rate of recurrence, larger tumor size and DNA aneuploidy. However, no direct relationship between breast carcinogenesis or prognosis and any specific tumor suppressor gene on 1p36 has been established. Recent elegant studies have identified CHD5 and more recently KIF1B as candidate tumor suppressor genes in this region, but no specific roles for these genes in breast cancer development have been demonstrated. The human PER3 gene is located within 1.5Mb of CHD5, and the mouse homologue is a member of the Period gene family that controls circadian rhythms. Members of the Period family of circadian rhythm genes (Per1 and Per2) have been implicated in cell cycle control, DNA damage responses and tumor progression. Although inactivation of mPer3 in the mouse germline has only subtle effects on circadian clock function, it has been shown that mPer3 transcripts exhibit a clear circadian rhythm both in the suprachiasmatic nucleus (SCN) and in mouse peripheral tissues. Similar data have been shown in human peripheral blood cells, where circadian oscillations were more robust for PER3 expression than for other clock genes including PER1 and PER2. The possible functions of PER3 in tumor development have not been explored, but links to breast cancer are supported by biochemical studies demonstrating the existence of complexes including proteins of the PER family together with the estrogen receptor, and by reports of association between a polymorphism in the human PER3 gene and breast cancer susceptibility. The location of the PER3 gene within a region that is commonly deleted in breast cancers suggested a possible link to epidemiological studies showing an association between disrupted sleep cycles and higher risk higher risk of developing breast cancer. We used a combination of human breast tumor analysis and mouse models to show that disruption of PER3 may serve as a prognostic biomarker of tumor recurrence in patients with ER+, Luminal A and/or ERBB2+ tumors. RESULTS Deletion of 1p36 and loss of PER3 genetic variants in breast cancers. We previously reported genome-wide array CGH profiles of 185 lymph node negative breast cancers from a Spanish cohort, of whom 85 received anthracycline chemotherapy (Chemo group), and 95 received no chemotherapy (non-Chemo group). To search for genetic events related to resistance to hormonal (Tamoxifen) therapy, we divided the non-Chemo group into two subgroups based on whether they had received hormonal treatment. Of the 95 patients in the non-Chemo group, 59 patients with ER and/or PgR positive tumors received Tamoxifen, whereas 36 did not receive any treatment. Analysis of CGH profiles for these patients revealed that deletion of chromosome 1p was associated with recurrence in this subgroup of ER+ Tamoxifen treated patients (p < 0.05 after multiple testing correction using method of Benjamini & Hoffberg) (Supplementary Fig. 1). The chromosome 1p36 locus is frequently deleted in many human tumors, but the region of deletion is large, and separate, non-overlapping chromosome fragments have been implicated. This suggests that multiple tumor suppressor genes are involved. We considered PER3 to be a good candidate for involvement in breast cancer because of its location within one of the minimal deletion regions on 1p36.2 (Refs. 5,6), as well as the epidemiological and mechanistic data linking circadian rhythm genes to hormone status and breast cancer. We therefore examined the copy number status of PER3 by quantitative TaqMan analysis in DNA samples from 180 breast cancer patients. The relationship between the frequency of deletion or copy number gain and clinico-pathological characteristics of the patients is shown in Supplementary Table 1. The number of copies of PER3 showed a significant gene dosage association with recurrence-free survival at 10 years (Fig. 1a, p= 0.01). The proportion of disease free surviving patients after 10 years was lowest in patients with single copy PER3 deletion (56% ± 8.6; red line) , compared to those with two (75% ± 4.0; blue line) or more (89% ± 5.6; green line) copies of the PER3 gene (Fig. 1a). Further analysis showed that the effect of PER3 deletion was most pronounced in the Tamoxifen treated group, with no significant association in the non-treated or chemotherapy-treated groups (Figs.1b-d). Among the 59 patients who only received Tamoxifen treatment (Fig. 1d), patients with single copy PER3 deletions had a significantly lower disease-free survival rate at 10 years (47% ±12) than those with normal PER3 (84%±6) or copy number gains (100% survival) (p=0.007). To look for potential inactivating mutations in PER3 in breast cancers, we initially sequenced the complete coding region of PER3 in a panel of 35 breast cancer cell lines. No clear pathogenic (nonsense or missense) mutation was identified. However many known and some other unknown polymorphisms and alternative splicing isoforms were found (see online supplementary data for full detailed description). One of the polymorphic variants identified by sequencing had been associated in other studies with breast cancer susceptibility and also with disruption of sleep homeostasis Low expression of PER3 is associated with reduced survival We next examined PER3 gene expression in 413 breast tumor expression arrays taken from two publicly available data sets (Van de Vijver 2002, n=295 and Chin 2007, n=118). A full description of the stratification of the patients into different subgroups according to PER3 expression together with disease-free survival curves for all patients in each sub-group is shown in Figures 2 and 3. Patients with lower PER3 expression (“PER3 low”, n=122) were significantly more likely to recur than those with normal or higher expression (“PER3 normal/high”, n=291) (Fig. 2a; p=0.013). Disease-free survival analysis showed that PER3 low patients had significantly worse survival rates than PER3 normal/high patients (p<0.001). ER status is an important predictor of recurrence and greatly influences treatment regimes. If low expression of PER3 segregates with ER status, any effect of low PER3 expression could be confounded with the effect of ER status. We therefore performed a subset analysis of PER3 in ER+ and ERtumors. Low PER3 levels were significantly associated with recurrence (p= 0.01) and shorter disease-free survival times (p<0.001) in patients with ER+, but not ERtumors (Fig. 2b). We conclude that the association between low PER3 expression and recurrence in the complete patient sample set was driven by the ER+ tumors, with no effect being detected in the ERtumors. These data are in agreement with the independent association between deletion of PER3 and recurrence specifically in the Tamoxifen-treated (ER positive) patients in Figure 1d. We next asked whether stratifying tumors according to their molecular subtype could reveal additional information. The tumors were labeled using a nearest centroid classifier and a label was only assigned if correlation with a target class was above 0.1 (Refs. 31,32). This resulted in samples labeled Luminal A (n=90), Luminal B (n=68), ERBB2 (n=56), Normal-like (n=17), Basal (n=73), or Unclassified (n=109) (Fig. 3 and supplementary Fig 4). Of these groups, low PER3 expression had significant association with recurrence only in Luminal A-type (p=0.007) or ERBB2-type tumors (p=0.03) (Fig. 3b). Disease-free survival analysis for Luminal A and ERBB2-type tumors indicated that PER3 low patients had lower disease free survival rates at 10 years than those patients with PER3 normal/high (28%± 10 vs 84%±4) for Luminal A (p<0.001) and (30%± 8 vs 68%±8) for ERBB2-type (p= 0.004). There was also a striking effect on overall survival rate at 10 years in all the patients and in the subgroups of ER positive, Luminal A and ERBB2 patients (Fig. 4): The ten year overall survival rate for ER+ patients with low PER3 was 55% ± 6 vs. 79% ± 3 for normal/high patients (p < 0.001) (Fig. 4b). The overall survival rate was 25% ± 8 for ERBB2 patients with low PER3, vs. 70% ± 7 for ERBB2 patients with normal/high PER3 (p<0.001) (Fig. 4f). The overall Survival rate at 10 years in Luminal-A patients with low PER3 was 34% ± 11 vs. 83% ± 3 for patients with normal/high PER3 (p<0.001) (Fig. 4g). Importantly, multivariate analysis showed that PER3 expression is significant independently from all the prognostic factors tested both for Disease Free Survival (p<0.001) and Overall survival (p=0.001) (Table 1). We next evaluated possible links between expression levels and probability of tumor recurrence for all 54 annotated genes in the 1p36.31-1p36.22 (chr1:6,084,440-9,512,808 (3.5 Mb in size))